Biologic
RCSB PDB 7URV
Tisagenlecleucel
Kymriah
- Mechanism of action
- Autologous anti-CD19 CAR-T cell therapy
- In plain language
- Your own T-cells are removed, genetically reprogrammed to recognize and attack cells carrying a marker called CD19, then infused back in.
- How it works
- Autologous T cells are collected via leukapheresis and genetically modified using a lentiviral vector to stably express a chimeric antigen receptor targeting CD19, comprising a single-chain variable fragment fused to CD8 hinge/transmembrane and 4-1BB/CD3-zeta signaling domains. The transduced cells are expanded ex vivo and cryopreserved. Following reinfusion after lymphodepleting chemotherapy, the CAR-T cells bind CD19 on target B cells, triggering activation, proliferation, and cytotoxic elimination of CD19-positive cells.
- Therapeutic applications
- Indicated for patients up to age 25 with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse; adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy; and adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
- Class
- CAR-T cell therapy
- Therapeutic area
- Oncology (B-cell malignancies)
View
Related compounds